The Impact of CD19+B-Cells and Some Important Parameters in Iraqi Hemodialysis Patients
Keywords:
Hemodialysis, B Cell Antigen CD19, parathyroid hormone, deterioration, vitamin D3.Abstract
Objective: The present study was designed to identify the effect of CD19+ B-cells in Hemodialysis (HD) patients compared to healthy volunteers and, also investigates its relationship with essential parameters parathyroid hormone (PTH), vitamin D3 (VitD3). Methods: A total of (60) clinically diagnosed patients and (30) healthy group, were collected from /February 2022 to July 2022/. Information was collected through a questionnaire designed for the present study. The serum levels of CD19 were evaluated using ELISA and serum remains were collected, for PTH and D3. Results: The result of the present study showed that the mean serum CD19 levels was significantly decreased (P < 0.001) in patients compared to healthy volunteers. Although the level of PTH was significantly higher (P < 0.001) in HD patients, the results showed a significant decrease in levels of D3 (P < 0.001). Furthermore, there was a highly significant positive correlation between B-cells levels and vitamin D3 level as well as showed this study a highly significant negative correlation between B-cells and PTH. Conclusion: Chronic kidney disease (CKD)-associated immunodeficiency has been associated with a decrease in B cells, and a substantial proportion of morbidity and mortality with advanced conditions; therefore, we can support the immune system of HD patients before deterioration. In future studies, a monthly examination of the CD19 + correlations with laboratory parameters may improve outcomes and disease. Also verifying the primary immune source that affects the disturbance of the natural system of the kidney, more studies are needed to shed light on therapies with antibodies.
Downloads
References
Turner NN, Lameire N, Goldsmith DJ,
Winearls CG, Himmelfarb J, Remuzzi G.
Oxford textbook of clinical nephrology.
Oxford University Press; 2015.
Hsu H-J, Wu I-W, Hsu K-H, Sun C-Y, Chen
C-Y, Lee C-C. Vitamin D deficiency,
cardiothoracic ratio, and long-term
mortality in hemodialysis patients. Sci
Rep. 2020;10(1):7533.
Kim KW, Chung BH, Jeon EJ, Kim B-M,
Choi BS, Park CW, et al. B cell-associated
immune profiles in patients with end-stage
renal disease (ESRD). Exp Mol Med.
;44(8):465–72.
Ruiz-Ortega M, Rayego-Mateos S, Lamas S,
Ortiz A, Rodrigues-Diez RR. Targeting
the progression of chronic kidney disease.
Nat Rev Nephrol. 2020;16(5):269–88.
Ene-Iordache B, Perico N, Bikbov B,
Carminati S, Remuzzi A, Perna A, et al.
Chronic kidney disease and cardiovascular
risk in six regions of the world (ISNKDDC): a cross-sectional study. Lancet
Glob Heal. 2016;4(5):e307–19.
Webster AC, Nagler E V, Morton RL, Masson
P. Chronic kidney disease. Lancet.
;389(10075):1238–52.
Mehrotra R, Piraino B. Preparing for
peritoneal dialysis. In: Chronic renal
disease. Elsevier; 2020. p. 1175–85.
Msaad R, Essadik R, Mohtadi K, Meftah H,
Lebrazi H, Taki H, et al. Predictors of
mortality in hemodialysis patients. Pan Afr
Med J. 2019;33.
Gisterå A, Hansson GK. The immunology of
atherosclerosis. Nat Rev Nephrol.
;13(6):368–80.
Wąsik M, Nazimek K, Bryniarski K.
Regulatory B cell phenotype and
mechanism of action: the impact of
stimulating conditions. Microbiol
Immunol. 2018;62(8):485–96.
Pahl M V, Gollapudi S, Sepassi L, Gollapudi
P, Elahimehr R, Vaziri ND. Effect of endstage renal disease on B-lymphocyte
subpopulations, IL-7, BAFF and BAFF
receptor expression. Nephrol Dial
Transplant. 2010;25(1):205–12Ghonemy TA, Farag SE, Soliman SA, ElOkely A, El-Hendy Y. Epidemiology and
risk factors of chronic kidney disease in the
El-Sharkia Governorate, Egypt. Saudi J
Kidney Dis Transplant. 2016;27(1):111.
Niemczyk S, Niemczyk L, RomejkoCiepielewska K. Basic endocrinological
disorders in chronic renal failure.
Endokrynol Pol. 2012;63(3):250–7.
Palmer SC, Hayen A, Macaskill P, Pellegrini
F, Craig JC, Elder GJ, et al. Serum levels
of phosphorus, parathyroid hormone, and
calcium and risks of death and
cardiovascular disease in individuals with
chronic kidney disease: a systematic review
and meta-analysis. Jama.
;305(11):1119–27.
Cohen G, Hörl WH. Immune dysfunction in
uremia—an update. Toxins (Basel).
;4(11):962–90.
Downloading IBM SPSS Statistics 28.0.
Collins AJ, Foley RN, Gilbertson DT, Chen
SC. US Renal Data System, USRDS 2010
Annual data report: atlas of chronic kidney
disease and end-stage renal disease in the
United States. Kidney Int Suppl.
;5:2–7.
Ayna TK, Akman B, Koçyiğit AÖ, Güleç D,
Tugmen C, Soyöz M. Flow cytometric
evaluation of T and B lymphocyte
percentage in chronic kidney disease. Med
Res J. 2017;2(1):29–33.
Saad K, Elsayh KI, Zahran AM, Sobhy KM.
Lymphocyte populations and apoptosis of
peripheral blood B and T lymphocytes in
children with end stage renal disease. Ren
Fail. 2014;36(4):502–7.
Abou-Bakr A, Hussein RR, Khalil E, Ahmed
E. The frequency of periodontitis in endstage renal disease on hemodialysis in a
sample of Egyptian population: multicenter clinical cross-sectional study. BMC
Oral Health. 2022;22(1):1.
Chang P-Y, Chien L-N, Lin Y-F, Wu M-S,
Chiu W-T, Chiou H-Y. Risk factors of
gender for renal progression in patients
with early chronic kidney disease.
Medicine (Baltimore). 2016;95(30).
Neugarten J, Golestaneh L. Influence of sex
on the progression of chronic kidney
disease. In: Mayo Clinic Proceedings.
Elsevier; 2019. p. 1339–56.
Molina M, Allende LM, Ramos LE,
Gutiérrez E, Pleguezuelo DE, Hernández
ER, et al. CD19+ B-cells, a new
biomarker of mortality in hemodialysis
patients. Front Immunol.
;9(JUN):1–8.
Lin J, Tang W, Liu W, Yu F, Wu Y, Fang X,
et al. Decreased B1 and B2 Lymphocytes
Are Associated With Mortality in Elderly
Patients With Chronic Kidney Diseases.
Front Med. 2020;7:75.
Vaziri ND, Pahl M V, Crum A, Norris K.
Effect of uremia on structure and function
of immune system. J Ren Nutr.
;22(1):149–56.
Lin J, Tang B, Feng Z, Hao W, Hu W.
Decreased B lymphocytes subpopulations
are associated with higher atherosclerotic
risk in elderly patients with moderate-tosevere chronic kidney diseases. BMC
Nephrol. 2021;22(1):396.
Maher FT, Majed HM, mubarak Mohammed
O. Relationship between Parathyroid
hormone and some electrolytes in patients
with End-Stage Renal Disease. Tikrit J
Pure Sci. 2017;22(4).
Nazzal ZA, Hamdan Z, Natour N, Barbar M,
Rimawi R, Salaymeh E. Prevalence of
Vitamin D Deficiency among Hemodialysis
Patients in Palestine: A Cross-Sectional Study.
Int J Nephrol. 2021;2021.
Mallet E, Castanet M. Primary
hyperparathyroidism in neonates and
children. In: Diseases of the parathyroid
glands. Springer; 2012. p. 289–98.
Cunningham J, Locatelli F, Rodriguez M.
Secondary hyperparathyroidism:
pathogenesis, disease progression, and
therapeutic options. Clin J Am Soc
Nephrol. 2011;6(4):913–21.
Warade JP, Kavitha R. Secondary
hyperparathyroidism in chronic kidney
disease. 2015;
Friedman E. Consequences and management
of hyperphosphatemia in patients with
renal insufficiency. Kidney Int.
;67:S1–7.
Patel NM, Gutiérrez OM, Andress DL,
Coyne DW, Levin A, Wolf M. Vitamin D
deficiency and anemia in early chronic
kidney disease. Kidney Int.
;77(8):715–20.Hou Y, Lu C, Lu K. Mineral bone disorders
in chronic kidney disease. Nephrology.
;23:88–94.
Elsheikh N, Sherif N, Abou Zeid S,
Eldamarawy M, Ali A, Sabry AI. The link
between bone disease and cardiovascular
complications in hemodialysis patients.
Electron Physician. 2016;8(6):2483.
Geara AS, Castellanos MR, Bassil C,
Schuller-Levis G, Park E, Smith M, et al.
Effects of Parathyroid Hormone on
Immune Function. Berzins S, editor. Clin
Dev Immunol. 2010;2010:418695.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
